A multicenter, randomized, double-blind, parallel group, 12 week study to evaluate the efficacy and safety of extended-release (ER) niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidemia.

Trial Profile

A multicenter, randomized, double-blind, parallel group, 12 week study to evaluate the efficacy and safety of extended-release (ER) niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2014

At a glance

  • Drugs Niacin/laropiprant (Primary) ; Atorvastatin; Simvastatin
  • Indications Dyslipidaemias; Hypercholesterolaemia; Lipid metabolism disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jul 2008 Actual patient number added (1250) as reported by ClinicalTrials.gov.
    • 16 Jul 2008 Actual end date added (Jul 2008) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top